Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 50-91-9] Floxuridine

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0097
Brand:	MCE
CAS:	50-91-9

Overview

MDL	MFCD00006530
Molecular Weight	246.19
Molecular Formula	C9H11FN2O5
SMILES	O=C(N1)N([C@H]2C[C@H](O)[C@@H](CO)O2)C=C(F)C1=O

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

[1]Small. 2022 Jul;18(30):e2202337.
[2]J Mol Med (Berl). 2019 Aug;97(8):1183-1193.

Summary

Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite . Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis ^[1] ^[2] . Floxuridine has antiviral effects against HSV and CMV ^[3] .

IC50 & Target

DNA synthesis

Bacterial

HSV

CMV

In Vitro

Floxuridine (0-25 μM; 4-24 hours) is affectd by inhibitors of PARP and its sensitivity of ovarian cancer cells is enhanced. Co-exposed to FdUrd and the PARP inhibitor markedly increases killing cell numbers when its compare to treatment alone in ovarian cancer cells ^[1] .
Floxuridine (300 μM; 4-24 hours) increases p-Chk1 and p-Chk2 in ovarian cancer cell lines. It may induce DNA damage and activate the ATM and ATR checkpoint signaling pathways ^[1] .
Floxuridine (0-2.5 μM; 24 hours) causes a G1/S-phase arrest and following removal of the FdUrd, the G1/S-phase-arrested cells moved synchronously through S phase and into G2/M ^[1] .
Floxuridine is against Mueller Hinton Broth and Tryptic Soy Broth with MIC values of 0.25 μM and 0.81 μM, respectively. It also reported to be a very potent inhibitor of staphylococcal growth (MIC, 0.025–0.00313 μM) ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	Ovarian cancer cells
Concentration:	0-25 μM
Incubation Time:	4, 8, 24 hours
Result:	Was potentiated the sensitivity by PARP inhibitors.

Western Blot Analysis ^[1]

Cell Line:	OVCAR-8 and SKOV3ip cells
Concentration:	300 μM
Incubation Time:	4, 8, 24 hours
Result:	Induced phosphorylation of Chk1 and Chk2 in two ovarian cancer cell lines

Cell Cycle Analysis ^[1]

Cell Line:	A2780, SKOV3ip, OVCAR-5, and OVCAR-3 ovarian cancer cells
Concentration:	0.5, 1.0, 1.5, 2.0, and 2.5 μM
Incubation Time:	24 hours
Result:	Induced cell arrest at G1/S-phase period.

In Vivo

Floxuridine (intraperitoneal injection; 0.5-1.25 mg/kg; once per day for 7 days or single dose) is sufficient to show statistically significant protection against S. aureus infection at 0.5 mg/kg for 7 days. In addition, 1.25 mg/kg single administration of the compound shows statistically significant protection against S. aureus infection ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice injected with S. aureus ^[2]
Dosage:	0.5-1.25 mg/kg
Administration:	once per day for 7 days or single dose
Result:	Was a very potent inhibitor for S. aureus infection in vivo.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03876574	Xiangya Hospital of Central South University	Nasopharyngeal Carcinoma\|Neoplasm Metastasis\|Liver	January 1, 2011	Phase 1
NCT00002783	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Gastric Cancer	May 1996	Phase 2
NCT00408551	Goshen Health System\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	November 2005	Phase 2
NCT00492999	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	May 2007	Phase 2
NCT03693807	Memorial Sloan Kettering Cancer Center	Colorectal Cancer\|Cholangiocarcinoma	October 18, 2018	Phase 2
NCT00004142	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	August 5, 1998	Phase 2
NCT00002842	City of Hope Medical Center\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	September 1994	Phase 2
NCT03493061	Sun Yat-sen University	Colo-rectal Cancer\|Liver Metastases	February 1, 2018	Phase 2
NCT00449163	University of Miami	Colorectal Cancer	March 1, 2006	Phase 2
NCT02529774	Ye Xu\|Fudan University	Resected Liver Metastases From Colorectal Cancer	September 2015	Phase 2\|Phase 3
NCT01525069	Washington University School of Medicine	Cholangiocarcinoma\|Liver Neoplasms	April 3, 2012	Phase 1
NCT00020501	National Institutes of Health Clinical Center (CC)\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	March 2001	Phase 3
NCT00008294	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	August 2000	Phase 1
NCT00001576	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Colorectal Neoplasm\|Liver Neoplasm\|Neoplasm Metastasis	July 1997	Phase 1
NCT05286814	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Metastatic Colorectal Cancer (Mcrc)\|Intrahepatic Cholangiocarcinoma (Icc)\|Colorectal Cancer\|Colorectal Neoplasms\|Cholangiocarcinoma\|Intrahepatic Bile Duct Cancer\|Bile Duct Cancer\|Bile Duct Neoplasms	October 24, 2022	Phase 2
NCT00026234	National Cancer Institute (NCI)\|NSABP Foundation Inc	Adenocarcinoma of the Colon\|Adenocarcinoma of the Rectum\|Liver Metastases\|Recurrent Colon Cancer\|Recurrent Rectal Cancer\|Stage IV Colon Cancer\|Stage IV Rectal Cancer	February 2002	Phase 2
NCT00522509	IRCCS San Raffaele	Colorectal Liver Metastases	December 1995
NCT01692704	University of Zurich	Cholangiocellular Carcinoma	April 2012	Phase 1\|Phase 2
NCT01938729	Memorial Sloan Kettering Cancer Center\|Ohio State University\|University of Texas Southwestern Medical Center\|Washington University School of Medicine	Intrahepatic Cholangiocarcinoma\|Peripheral Cholangiocarcinoma\|Cholangiolar Carcinoma\|Cholangiocellular Carcinoma) (ICC)	September 5, 2013	Phase 1
NCT01749397	National Cancer Institute (NCI)	Stage IV Fallopian Tube Cancer AJCC v6 and v7\|Stage IV Ovarian Cancer AJCC v6 and v7\|Stage IV Primary Peritoneal Cancer AJCC v7	December 7, 2012	Phase 1
NCT00003753	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	September 1998	Phase 2
NCT04552093	The Netherlands Cancer Institute\|Erasmus Medical Center	Colorectal Neoplasms	September 9, 2020	Phase 2\|Phase 3
NCT00006038	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Esophageal Cancer\|Gastric Cancer	February 2000	Phase 2
NCT00848783	NYU Langone Health	Gastric Cancer\|Gastric Adenocarcinoma\|Esophageal Cancer	May 2008	Phase 2
NCT00004103	NYU Langone Health\|National Cancer Institute (NCI)	Gastric Cancer	July 1998	Phase 2
NCT00448682	University of Miami	Gastric Cancer	June 2005	Phase 2
NCT00858338	NYU Langone Health\|Food and Drug Administration (FDA)	Gastric Cancer\|Stomach Cancer	December 2002	Phase 2
NCT00019760	National Institutes of Health Clinical Center (CC)	Recurrent Colon Cancer\|Liver Metastases\|Stage IV Rectal Cancer\|Recurrent Rectal Cancer\|Stage IV Colon Cancer	April 1999	Phase 2
NCT00059930	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)\|University of Medicine and Dentistry of New Jersey	Colorectal Cancer\|Metastatic Cancer	January 2003	Phase 1
NCT00268463	NSABP Foundation Inc\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	January 2006	Phase 3
NCT03856658	Spectrum Health Hospitals	Pancreatic Adenocarcinoma\|Liver Metastases	February 5, 2019	Phase 2
NCT04668976	Benaroya Research Institute\|Virginia Mason Hospital+Medical Center	Colorectal Cancer\|Cholangiocarcinoma	November 25, 2020	Phase 2
NCT00410956	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Liver Cancer	May 2007	Phase 2
NCT00063960	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	August 2003	Phase 2
NCT00448760	University of Miami	Esophageal Cancer	October 2004	Phase 2
NCT03678428	Sun Yat-sen University	Metastatic Colorectal Cancer\|Liver Metastases	December 31, 2021	Phase 3
NCT00587067	Memorial Sloan Kettering Cancer Center\|Wake Forest University	Hepatic Cancer	June 2003	Phase 2
NCT00005049	NYU Langone Health\|National Cancer Institute (NCI)	Colorectal Cancer\|Gastric Cancer\|Gastrointestinal Carcinoid Tumor\|Gastrointestinal Stromal Tumor\|Ovarian Cancer\|Peritoneal Cavity Cancer\|Small Intestine Cancer	May 1997	Phase 2
NCT00645710	City of Hope Medical Center	Liver Metastases\|Recurrent Colon Cancer\|Recurrent Rectal Cancer\|Stage IV Colon Cancer\|Stage IV Rectal Cancer	February 11, 2005	Phase 1\|Phase 2
NCT04251715	OHSU Knight Cancer Institute\|Oregon Health and Science University	Liver and Intrahepatic Bile Duct Carcinoma\|Stage III Intrahepatic Cholangiocarcinoma AJCC v8\|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8\|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8\|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8\|Unresectable Intrahepatic Cholangiocarcinoma	April 28, 2021	Phase 2
NCT04898504	Oslo University Hospital	Colorectal Cancer\|Liver Metastases\|Chemotherapy Effect	August 2021	Phase 2
NCT00005860	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Cancer	April 2000	Phase 1
NCT03069950	Memorial Sloan Kettering Cancer Center\|The Cleveland Clinic\|Oregon Health and Science University\|Queens Cancer Center of Queens Hospital\|Washington University School of Medicine	Colorectal Adenocarcinoma Metastatic to the Liver	February 28, 2017	Phase 2
NCT01862315	Memorial Sloan Kettering Cancer Center	Intrahepatic Cholangiocarcinoma\|Peripheral Cholangiocarcinoma\|Cholangiolar Carcinoma\|Cholangiocellular Carcinoma	May 2013	Phase 2
NCT04276090	Michael J Cavnar, MD\|University of Kentucky	Bile Duct Neoplasms\|Colorectal Neoplasms	May 1, 2020	Not Applicable
NCT00002716	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Colorectal Cancer\|Metastatic Cancer	January 1996	Phase 3
NCT04891289	Memorial Sloan Kettering Cancer Center	Intrahepatic Cholangiocarcinoma	May 7, 2021	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL ( 507.74 mM ; Need ultrasonic)

H ₂ O : ≥ 50 mg/mL ( 203.10 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.0619 mL	20.3095 mL	40.6190 mL
5 mM	0.8124 mL	4.0619 mL	8.1238 mL
10 mM	0.4062 mL	2.0310 mL	4.0619 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (406.19 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (8.45 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (8.45 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (8.45 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Huehls AM, et al. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.Cancer Res. 2011 Jul 15;71(14):4944-54.
[2] Yeo WS, et al. The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus.Sci Rep. 2018 Feb 6;8(1):2521.
[3] Langman J, et al. Floxuridine and its influence on postnatal cerebellar development. Pediatr Res. 1972 Oct;6(10):758-64.

Synonyms

Uridine, 2′-deoxy-5-fluoro-

2′-Deoxy-5-fluorouridine

Floxuridine

5-Fluorodeoxyuridine

5-Fluoro-2′-deoxyuridine

5-Fluorouracil 2′-deoxyriboside

5-Fluorouracil deoxyriboside

NSC 27640

1-(2-Deoxy-β-D-ribofuranosyl)-5-fluorouracil

5-Fluoro-2′-deoxy-β-uridine

FUDR

Floxuridin

FdUrd

NSC 26740

5-FudR

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart